J

Johnson & Johnson

Makes prescription drugs and medical devices

Product Safety Head - Solid Tumors

Full-TimeUpdated Deadline 11/29/26
$196k - $342.7k
Expert
MD
Horsham, PA, USA+2 moreMore locations: Raritan, NJ, USA | Hopewell Township, NJ, USA
Hybrid
Biology & Biotech

About the job

Requirements
  • A physician (MD or equivalent) with at least 10 years of substantial pharmaceutical industry experience; clinical experience is highly preferred.
  • Management experience supervising a group of employees, strong leadership skills, and the ability to thrive in a global, matrix environment.
  • Significant skills in clinical medicine and pharmacovigilance, including post-marketing safety assessment experience.
  • Knowledge of oncology products and associated pharmacovigilance guidelines and the global regulatory framework.
  • In-depth knowledge of drug development, pharmacology, clinical trial methodology and design, medical monitoring of trials, benefit-risk assessment, and safety assessment of marketed and developmental compounds.
  • A track record handling difficult safety issues and clinical safety data, and interacting with domestic and international regulatory departments and agencies.
  • Ability to manage multiple critical issues simultaneously, critically evaluate data from clinical trials, post-marketing environments and literature, and assess the data's strategic importance.
  • Ability to influence, negotiate and communicate with internal and external customers.
  • Ability to develop, implement, communicate and influence policy and strategy internally and externally.
  • Excellent verbal and written communication, including formal presentation skills.
  • Knowledge of Good Clinical Practices and pharmacovigilance regulatory requirements, clinical trial conduct, and contributions to regulatory filings, pharmacovigilance documents and risk management plans.
  • Fluency in written and spoken English.
  • Working knowledge of Microsoft software, including Excel and Word.
Responsibilities
  • Shape safety strategy and risk management for assigned pharmaceutical products during drug development and post-marketing.
  • Partner with the TASH, the Head of Global Safety Strategy and Risk Minimization, the Chief Safety Officer, the Chief Medical Officer for JJ IM, the Qualified Person for Pharmacovigilance for JJ IM, other JJ IM R&D leaders, and other GMS groups to assess, respond to and communicate product safety concerns throughout the product lifecycle.
  • Provide oversight, medical expertise and leadership to Product Medical Safety Officers and safety analysis scientists for end-to-end medical safety strategy for assigned products.
  • Contribute to key regulatory documents, including ad hoc reports, Health Hazard Evaluations, Clinical Overviews, PBRERs/PSURs and REMS/RMPs, and serve as the designated GMS leader and signatory on program Labeling Committees.
  • Coordinate with Clinical TA, Medical Affairs, Global Regulatory Affairs and QPPV Pharma colleagues to implement and comply with post-marketing risk management commitments.
  • Work with GSSRM TASHs and TALs, QPPV Pharma and other GMS functions to align medical safety processes, implement process improvements and improve operational efficiency.
  • Serve as the Safety Representative on the Sponsor Committee for the Independent Data Monitoring Committee.
  • Provide input on pharmaceutical candidate licensing and acquisition.
  • Support the TASH and GSSRM Head in managing the annual budget and planned resource allocation to meet portfolio objectives.
  • Support regulatory inspection readiness, inspections and corrective and preventive actions.
  • Develop or revise standard operating procedures as a Business Process Owner or functional stakeholder.
  • Promote diversity, equity and inclusion by hiring and retaining diverse talent and fostering an inclusive community.
  • Act ethically and responsibly, keeping patient safety paramount.
  • Lead written and verbal interactions with regulatory authorities regarding safety and risk management for the CTP.
  • Ensure drug safety activities and processes comply with global legislation and regulatory requirements.
  • Grow, attract, retain and develop talent, and build teams to support organizational effectiveness, transparency and communication.
Desired Qualifications
  • Clinical experience.
  • Oncology therapeutic area experience.
  • Publication and journal article writing skills.
  • Experience presenting to technical and lay groups at public meetings.
  • Clinical Operations.
  • Compliance Management.
  • Compliance Risk.
  • Developing Others.
  • Inclusive Leadership.
  • Industry Analysis.
  • Leadership.
  • Medicines and Device Development and Regulation.
  • Operations Management.
  • Quality Control (QC).
  • Research Ethics.
  • Risk Management.
  • Risk Management Framework.
  • Safety Investigations.
  • Safety-Oriented.
  • Serious Adverse Event Reporting.
  • Standard Operating Procedure (SOP).
  • Tactical Planning.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
The Irish Times
Oct 28th, 2026
Johnson & Johnson buys Irish stroke care firm in multimillion euro deal

Sale of Neuravi is largest deal for a venture-backed medtech in Europe since 2009

Associated Press
Oct 27th, 2026
Pomerantz investigates Johnson & Johnson after 5.73% share drop on talc charges and MedTech miss

Pomerantz LLP is investigating whether Johnson & Johnson (J&J) and some of its officers or directors engaged in securities fraud or other unlawful business practices. The law firm advises affected investors to contact Danielle Peyton at [email protected]. On October 13, 2026, J&J reported third-quarter GAAP net earnings of $210 million, or $0.09 per share. Multi-billion dollar special charges tied to its talc litigation settlement weighed on the result. Its MedTech segment grew only 2.5% to $8.64 billion, a second straight revenue miss. J&J cited pricing constraints in China and disruption in the Middle East. The stock fell $15.12, or 5.73%, to close at $248.61 that day.

Yahoo Finance
Oct 27th, 2026
J&J sees $34.7M net ETF outflow, extending selling streak to four days

ETFs sold a net $34.7 million of Johnson & Johnson stock on Friday, October 23, extending a four-day run of net selling. SPY led the move, cutting $34.6 million, or 0.44% of its stake. XLV sold $24.6 million and DIA $6.3 million. More funds bought than sold, with 26 ETFs adding shares and 17 cutting them, but their purchases were smaller. Net outflows were $55.2 million on October 22, $54.1 million on October 21, and $19.8 million on October 20. A net inflow of $38.1 million came on October 19. Johnson & Johnson has a market cap of $641.1 billion. It reported $99.35 billion in trailing-12-month revenue, up 7.0% over one year.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.